- Posts: 72
- Joined: Mon Apr 23, 2012 9:47 am
He was fairly stable on the Tafinlar from 2013 - 2018 with the exception of two brain mets. Added Keytruda after the second met and is "sort of" NED since January 2019. His scans in Jan were clear in both body and brain but the April scans showed some residual activity in a previously active lymph node that was not apparent in the Jan scans. We're waiting for his scans in July to see what's happening. Side effects from the dual therapy are primarily fatigue and muscle/joint pain. Also had a recurrence of Uveitis which he has had on and off since 2013. All in all, not much difference in the side effects after adding Keytruda.
- Posts: 11221
- Joined: Wed Jan 02, 2008 12:09 am
Sounds like good news! We have to get creative with what we have. I didn't see any great new discoveries out of ASCO otherwise. But new markers may be the pathway to better drugs. Yes, don't ask how the insurance covered this, just go with it! Sounds like you have a great medical team. Thanks for checking in.
Melanoma International Foundation
Users browsing this forum: Google [Bot] and 11 guests